Yorkshire Enhanced Stop Smoking (YESS) study: a protocol for a randomised controlled trial to evaluate the effect of adding a personalised smoking cessation intervention to a lung cancer screening programme

IntroductionIntegration of smoking cessation (SC) into lung cancer screening is essential to optimise clinical and cost effectiveness. The most effective way to use this ‘teachable moment’ is unclear. The Yorkshire Enhanced Stop Smoking study will measure the effectiveness of an SC service integrate...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMJ open Ročník 10; číslo 9; s. e037086
Hlavní autoři: Murray, Rachael L, Brain, Kate, Britton, John, Quinn-Scoggins, Harriet D, Lewis, Sarah, McCutchan, Grace M, Quaife, Samantha L, Wu, Qi, Ashurst, Alex, Baldwin, David, Crosbie, Philip A J, Neal, Richard D, Parrott, Steve, Rogerson, Suzanne, Thorley, Rebecca, Callister, Matthew EJ
Médium: Journal Article
Jazyk:angličtina
Vydáno: England British Medical Journal Publishing Group 10.09.2020
BMJ Publishing Group LTD
BMJ Publishing Group
Edice:Protocol
Témata:
Collaboration
Consent
Data collection
Early Detection of Cancer
Electronic Nicotine Delivery Systems
Health services
Humans
Intervention
Lung cancer
Lung Neoplasms - diagnostic imaging
Medical screening
Mortality
protocols & guidelines
Public health
Randomized Controlled Trials as Topic
Smoking
Smoking and Tobacco
Smoking Cessation
Systematic review
Wales
Wales
United Kingdom > UK
United States > US
protocols & guidelines
CT
public health
ISSN:2044-6055, 2044-6055
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:IntroductionIntegration of smoking cessation (SC) into lung cancer screening is essential to optimise clinical and cost effectiveness. The most effective way to use this ‘teachable moment’ is unclear. The Yorkshire Enhanced Stop Smoking study will measure the effectiveness of an SC service integrated within the Yorkshire Lung Screening Trial (YLST) and will test the efficacy of a personalised SC intervention, incorporating incidental findings detected on the low-dose CT scan performed as part of YLST.Methods and analysisUnless explicitly declined, all smokers enrolled in YLST will see an SC practitioner at baseline and receive SC support over 4 weeks comprising behavioural support, pharmacotherapy and/or a commercially available e-cigarette. Eligible smokers will be randomised (1:1 in permuted blocks of random size up to size 6) to receive either an enhanced, personalised SC support package, including CT scan images, or continued standard best practice. Anticipated recruitment is 1040 smokers (January 2019–December 2020). The primary objective is to measure 7-day point prevalent carbon monoxide (CO) validated SC after 3 months. Secondary outcomes include CO validated cessation at 4 weeks and 12 months, self-reported continuous cessation at 4 weeks, 3 months and 12 months, attempts to quit smoking and changes in psychological variables, including perceived risk of lung cancer, motivation to quit smoking tobacco, confidence and efficacy beliefs (self and response) at all follow-up points. A process evaluation will explore under which circumstances and on which groups the intervention works best, test intervention fidelity and theory test the mechanisms of intervention impact.Ethics and disseminationThis study has been approved by the East Midlands-Derby Research Ethics Committee (18/EM/0199) and the Health Research Authority/Health and Care Research Wales. Results will be disseminated through publication in peer-reviewed scientific journals, presentation at conferences and via the YLST website.Trial registration numbersISRCTN63825779, NCT03750110.
Bibliografie:Protocol
ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Undefined-1
content type line 23
ISSN:2044-6055
2044-6055
DOI:10.1136/bmjopen-2020-037086